Egyptian healthtech company Reme-D has raised $1.45 million in a pre-Series A funding round led by Anara Impact Capital, with participation from the Global Innovation Fund, Africa Health Ventures and other investors.
The new funding will be used to expand the company’s manufacturing capabilities, enter new African markets and diversify its molecular diagnostics portfolio. Reme-D is also developing diagnostic tests for genetic disorders and cancer while enhancing the temperature resistance of its products to ease transportation and storage in regions with limited healthcare infrastructure.
Founded in 2023 by Salma Tammam, the Cairo-based company develops molecular diagnostic tests for diseases such as tuberculosis, HIV, hepatitis and human papillomavirus (HPV). The company said it has commercialised 30 diagnostic products and delivered more than 550,000 tests to customers across Egypt, Kenya and Sudan.
As part of its growth plans, Reme-D will move into a new 1,500-square-metre production facility and upgrade its manufacturing equipment. The expansion is expected to increase production capacity by ten times. The company’s workforce has also grown significantly, rising from five employees to about 50.
Recently, Reme-D developed a customised solar-powered mobile laboratory commissioned by the World Health Organization’s Egypt office. The mobile unit is supporting the Egyptian Ministry of Health’s efforts to monitor vector-borne diseases in remote communities.
The company had previously secured $500,000 from the Global Innovation Fund to scale its molecular diagnostic solutions. The latest investment is expected to accelerate Reme-D’s mission of expanding access to affordable, locally manufactured diagnostic technologies across Africa and other underserved markets.
About The Author
